The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Cardiovascular disease in metabolic-associated fatty liver disease
2Department of Hepatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Abstract
Purpose of review: Fatty liver disease is increasingly common worldwide and is associated with an increased risk of cardiovascular disease (CVD).
Recent findings: This review describes the cardiovascular outcomes, clinical assessment and management as well as the impact of emerging drug treatment on CVD risk.
Summary: Patients with fatty liver require CVD risk assessment including consideration of statin therapy. Emerging therapeutic drugs for fatty liver may have both adverse and beneficial effects on CVD risk.